FORMRISE adopts AM Solutions’ S1 system, cutting SLS post‑processing time and reducing material and energy use.

SELLAS Life Sciences (SLS) is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst.

Following the recent successful test flight of NASA's Artemis II mission around the moon, NASA rolled out the core stage, or ...

Discover how medical 3D printing creates patient-specific devices and custom prosthetics. Read our guide to clinical ...

Following the recent success of its Artemis II mission, NASA has taken the next step by rolling out the core stage of its SLS ...

American space agency NASA published the initial details of the Artemis II Moon mission hardware review, everything worked as ...

Welcome to Edition 8.38 of the Rocket Report! The big news this week concerned the third launch of the New Glenn rocket. The ...

Parts of the rocket that will be used in the upcoming Artemis III mission were built in Huntsville.

Following the recent successful test flight of NASA’s Artemis II mission around the Moon, NASA rolled out the core stage.

Anticipated updates on the company’s leukemia drug SLS009 did not land, dampening near-term catalyst momentum. ・Earlier studies showed SLS009 triggered leukemia cell death and remained active in ...

Boeing has shipped a major section of the Space Launch System (SLS) core stage for NASA’s Artemis III mission, marking a ...

Dagco added 451,240 shares, making Sellas its second-largest holding at 1.01% of portfolio weight. ・The stake increase comes ahead of AACR presentation of preclinical data on SLS009, Sellas’ CDK9 ...